Biosimilars Market - Global Forecast To 2035
商品番号 : SMB-7579
出版社 | MarketsandMarkets |
出版年月 | 2025年6月 |
ページ数 | 392 |
図表数 | 478 |
価格タイプ | シングルユーザライセンス |
価格 | USD 4,950 |
種別 | 英文調査報告書 |
本調査レポートでは、バイオシミラー市場を、バイオシミラー市場別、医薬品クラス別(モノクローナル抗体(リツキシマブ、インフリキシマブ、アダリムマブ、トラスツズマブ、ペムブロリズマブ、デュピルマブ、ウステキヌマブ、リサンキズマブ、その他のモノクローナル抗体)、顆粒球コロニー刺激因子、インスリン、エリスロポエチン、遺伝子組換えヒト成長ホルモン、エタネルセプト、フォリトロピン、テリパラチド、インターフェロン、抗凝固薬、アフリベルセプト、GLP-1拮抗薬、その他の製品)、適応症別(腫瘍、炎症性および自己免疫疾患、慢性疾患、血液疾患、成長ホルモン欠乏症、感染症、2型糖尿病、肥満症、その他の適応症)、地域別(北米、欧州、アジア太平洋、ラテンアメリカ、中東、アフリカ)に分類しています。
本レポートは、バイオシミラー市場の成長に影響を与える主要な要因(促進要因、制約要因、課題、機会など)に関する詳細な情報を網羅しています。主要業界プレーヤーの詳細な分析により、事業概要、製品、ソリューション、主要戦略、提携、パートナーシップ、契約に関する洞察を提供しています。バイオシミラー市場に関連する新規承認/上市、提携、買収、および最近の動向についても解説しています。
The global biosimilars market is projected to reach USD 72.29 billion by 2035 from USD 35.04 billion in 2025, at a CAGR of 7.5% during the forecast period. The expansion of the biosimilars market has been predominantly fueled by heightened awareness and education regarding the safety, efficacy, and interchangeability of biosimilar products. Additionally, favorable insurance coverage and reimbursement structures implemented by both public and private payers have played a crucial role in this growth, alongside an increasing demand for cost-effective biologic therapies. Nonetheless, the market faces challenges from escalating complexities in the manufacturing processes and intensifying competition, leading to significant pricing pressures that may hinder further growth.
世界のバイオシミラー市場は、2025年の350.4億米ドルから2035年には722.9億米ドルに達し、予測期間中に7.5%の年平均成長率(CAGR)で成長すると予測されています。バイオシミラー市場の拡大は、主にバイオシミラー製品の安全性、有効性、互換性に関する意識の高まりと教育によって推進されてきました。さらに、費用対効果の高い生物学的療法に対する需要の高まりと並んで、公的および民間の保険支払者によって実施された有利な保険適用範囲と償還制度もこの成長に重要な役割を果たしてきました。しかしながら、市場は製造プロセスの複雑さの増大と競争の激化という課題に直面しており、さらなる成長を妨げる可能性のある大きな価格圧力につながっています。

The monoclonal antibodies segment is expected to grow at the highest CAGR during the study period.
Monoclonal antibodies (mAbs) such as infliximab, rituximab, adalimumab, trastuzumab, pembrolizumab, dupilumab, Ustekinumab, Risankizumab, and others are primarily utilized for the treatment of autoimmune disorders, various cancers, chronic illnesses, and select infectious diseases. The anticipated rise in patient demographics, coupled with increasing adoption rates and the impending patent expirations of several key biologics, is projected to drive demand in the mAb sector. These therapeutics are extensively employed in managing chronic and life-threatening conditions, notably cancer, rheumatoid arthritis, psoriasis, and inflammatory bowel disease, which are experiencing heightened global prevalence due to an aging populace and lifestyle-related risk factors. The emergence of biosimilars for these mAbs offers an opportunity to mitigate healthcare expenditures and improve access to essential therapies. With over 10-15 leading mAbs facing patent expirations within the next decade, competition is poised to intensify, piquing the interest of pharmaceutical companies in the mAb market. The affordability and extensive applicability of mAb biosimilars, particularly in oncology and autoimmune therapies, are likely to significantly contribute to future market growth.

The US is expected to grow at the highest CAGR in the global biosimilars market from 2025 to 2035.
The United States is projected to experience the highest compound annual growth rate (CAGR) in the global biosimilars market between 2025 and 2035. This rapid growth is largely driven by the expiration of patents on several blockbuster biologics and the increasingly favorable regulatory environment established by the Biologics Price Competition and Innovation Act (BPCIA). Over the next decade, the US is expected to see biosimilar entries for major biologics such as Keytruda (pembrolizumab), Stelara (ustekinumab), and Eylea (aflibercept), which are all multi-billion-dollar products. These launches will significantly expand the addressable market for biosimilars, particularly in oncology, immunology, and ophthalmology. Additionally, the growing payer and provider acceptance of biosimilars in the US healthcare system is accelerating uptake. For instance, biosimilars of adalimumab (Humira), the highest-selling biologic in the US for over a decade, began launching in 2023 with multiple entrants such as Amgen, Boehringer Ingelheim, and Sandoz. Early signs show that competitive pricing is starting to drive formulary access and payer adoption. Moreover, legislative and policy efforts, including Medicare reforms and price transparency regulations, are expected to further incentivize biosimilar use, leading to cost savings and greater market penetration. As more biosimilars gain interchangeable status, market dynamics are likely to mirror those seen in generics, thus supporting sustained growth in the US biosimilars sector over the next decade.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side-70% and Demand Side-30%
- By Designation: Managers-45%, CXO and Directors-30%, and Executives-25%
- By Region: North America-40%, Europe-25%, the Asia Pacific-25%, Latin America-5%, and the Middle East & Africa-5%
List of Key Companies Profiled in the Report:
Sandoz Group AG (Switzerland), Pfizer Inc. (US), Amgen Inc. (US), Celltrion, Inc. (South Korea), Biocon (India), Dr. Reddy’s Laboratories Ltd. (India), Eli Lilly and Company (US), Teva Pharmaceutical Industries Ltd. (Israel), Fresenius Kabi AG (Germany), STADA Arzneimittel AG (Germany), Boehringer Ingelheim International GmbH (Germany), Samsung Biologics Co., Ltd. (South Korea), Amneal Pharmaceuticals LLC (US), Coherus BioSciences, Inc. (US), Bio-Thera Solutions, Ltd. (China), Aprogen Inc. (South Korea), Shanghai Henlius Biopharmaceuticals, Inc. (China).

Research Coverage:
This research report categorizes the biosimilars market by biosimilars market, by drug class [monoclonal antibodies (rituximab, infliximab, adalimumab, trastuzumab, Pembrolizumab, Dupilumab, Ustekinumab, Risankizumab, and other monoclonal antibodies), granulocyte colony-stimulating factor, insulin, erythropoietin, recombinant human growth hormone, etanercept, follitropin, teriparatide, interferons, anticoagulants, Aflibercept, GLP-1 antagonist, and other products), By indication (oncology, inflammatory and autoimmune diseases, chronic diseases, blood disorders, growth hormone deficiency, infectious diseases, type II diabetes, obesity, and other indications) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the biosimilars market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the biosimilars market.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing them with the closest approximations of the revenue numbers for the overall biosimilars market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (rising global demand for affordable alternatives to expensive biologic therapies, increasing number of biosimilar launches and approvals, Impending and ongoing patent expiry of blockbuster biologics, entry of emerging players with cost-efficient manufacturing capabilities), restraints (manufacturing complexities and high cost of biosimilars, intense competition, and pricing pressure among market players), opportunities (launch of GLP-1 biosimilars, increasing strategic partnerships and collaborations among biosimilar manufacturers, and growing focus on advanced R&D operating models), and Challenges (increased market competition between biosimilar manufacturers and originator biologic companies).
- Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the biosimilars market.
- Market Development: Comprehensive information about lucrative markets; the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the biosimilars market.
Table of Contents
1 INTRODUCTION 34
1.1 STUDY OBJECTIVES 34
1.2 MARKET DEFINITION 34
1.3 STUDY SCOPE 35
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 35
1.3.2 INCLUSIONS & EXCLUSIONS 36
1.3.3 YEARS CONSIDERED 36
1.3.4 CURRENCY CONSIDERED 36
1.4 STAKEHOLDERS 37
1.5 SUMMARY OF CHANGES 37
2 RESEARCH METHODOLOGY 39
2.1 RESEARCH DATA 39
2.1.1 SECONDARY DATA 40
2.1.1.1 Objectives of secondary research 40
2.1.1.2 Key data from secondary sources 41
2.1.2 PRIMARY DATA 41
2.1.2.1 Breakdown of primaries 42
2.1.2.2 Key objective of primary research 42
2.2 MARKET ESTIMATION 43
2.2.1 GLOBAL MARKET ESTIMATION 43
2.2.1.1 Company revenue analysis (bottom-up approach) 43
2.2.1.1.1 Revenue share analysis of Sandoz Group AG 44
2.2.1.2 MnM repository analysis 45
2.2.1.3 Primary interviews 45
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 46
2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 46
2.3 MARKET GROWTH RATE PROJECTIONS 47
2.4 DATA TRIANGULATION 50
2.5 STUDY ASSUMPTIONS 51
2.6 RESEARCH LIMITATIONS 51
2.7 RISK ANALYSIS 52
3 EXECUTIVE SUMMARY 53
4 PREMIUM INSIGHTS 57
4.1 BIOSIMILARS MARKET OVERVIEW 57
4.2 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS AND COUNTRY 58
4.3 BIOSIMILARS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
4.4 BIOSIMILARS MARKET: EMERGING VS. DEVELOPED MARKETS,
2025 VS. 2035 (USD MILLION) 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
5.2.1 DRIVERS 61
5.2.1.1 Rising global demand for affordable alternatives to expensive biologic therapies 61
5.2.1.2 Increasing number of biosimilar launches and approvals 62
5.2.1.3 Impending and ongoing patent expiry of blockbuster biologics 65
5.2.1.4 Entry of emerging players with cost-efficient
manufacturing capabilities 66
5.2.2 RESTRAINTS 67
5.2.2.1 Manufacturing complexities and high cost of biosimilars 67
5.2.2.2 Intense competition and pricing pressure among market players 67
5.2.3 OPPORTUNITIES 68
5.2.3.1 Launch of GLP-1 biosimilars 68
5.2.3.2 Increasing strategic partnerships and collaborations among biosimilar manufacturers 68
5.2.3.3 Growing focus on advanced R&D operating models 69
5.2.4 CHALLENGES 69
5.2.4.1 Increased market competition between biosimilar manufacturers and originator biologic companies 69
5.3 TECHNOLOGY ANALYSIS 70
5.3.1 KEY TECHNOLOGIES 70
5.3.1.1 Advanced bioprocessing & manufacturing technologies 70
5.3.1.2 Analytical & characterization techniques 70
5.3.2 COMPLEMENTARY TECHNOLOGIES 71
5.3.2.1 AI & ML 71
5.3.2.2 Lab automation & robotics 71
5.3.3 ADJACENT TECHNOLOGIES 71
5.3.3.1 Microbial fermentation 71
5.3.3.2 3D bioprinting & high-density cell culture 72
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 72
5.5 VALUE CHAIN ANALYSIS 74
5.6 ECOSYSTEM ANALYSIS 75
5.6.1 ROLE IN ECOSYSTEM 76
5.7 PATENT ANALYSIS 77
5.7.1 LIST OF KEY PATENTS 78
5.8 PIPELINE ANALYSIS 80
5.8.1 BIOSIMILAR PRODUCTS IN CLINICAL PIPELINE 80
5.8.2 LIST OF KEY BIOLOGICS TO GO OFF-PATENT 83
5.9 REGULATORY ANALYSIS 84
5.9.1 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 84
5.9.2 REGULATORY FRAMEWORK 86
5.10 REIMBURSEMENT SCENARIO ANALYSIS 88
5.11 PRICING ANALYSIS 91
5.11.1 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY KEY PLAYER, 2022–2024 91
5.11.2 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY REGION, 2022–2024 93
5.12 KEY CONFERENCES & EVENTS, 2025–2026 95
5.13 PORTER’S FIVE FORCES ANALYSIS 96
5.13.1 THREAT OF NEW ENTRANTS 97
5.13.2 THREAT OF SUBSTITUTES 97
5.13.3 BARGAINING POWER OF SUPPLIERS 97
5.13.4 BARGAINING POWER OF BUYERS 97
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 98
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 98
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 98
5.14.2 KEY BUYING CRITERIA 99
5.15 INVESTMENT & FUNDING SCENARIO 101
5.16 IMPACT OF AI/GEN AI ON BIOSIMILARS MARKET 102
5.17 IMPACT OF 2025 US TARIFF ON BIOSIMILARS MARKET 103
5.17.1 INTRODUCTION 103
5.17.2 KEY TARIFF RATES 103
5.17.3 PRICE IMPACT ANALYSIS 104
5.17.4 IMPACT ON COUNTRY/REGION 105
5.17.4.1 North America 105
5.17.4.1.1 US 105
5.17.4.2 Europe 105
5.17.4.3 Asia Pacific 106
5.17.5 IMPACT ON UPSTREAM MANUFACTURING INDUSTRIES 106
6 BIOSIMILARS MARKET, BY DRUG CLASS 107
6.1 INTRODUCTION 108
6.2 MONOCLONAL ANTIBODIES 109
6.2.1 RITUXIMAB 112
6.2.1.1 Rising incidences of autoimmune diseases and cancer to
boost segment growth 112
6.2.2 INFLIXIMAB 115
6.2.2.1 Loss of patent exclusivity to fuel adoption for treating
autoimmune diseases 115
6.2.3 ADALIMUMAB 118
6.2.3.1 Cost-effectiveness and improved patient access to support
segment growth 118
6.2.4 TRASTUZUMAB 121
6.2.4.1 Rising incidence of breast cancer to spur market growth 121
6.2.5 PEMBROLIZUMAB 124
6.2.5.1 Expansion of immunotherapy in oncology to propel segment growth 124
6.2.6 DUPILUMAB 126
6.2.6.1 High cost of originator therapy and ongoing label expansions to increase demand for affordable biosimilars 126
6.2.7 USTEKINUMAB 129
6.2.7.1 High annual treatment costs of original drug to augment
segment growth 129
6.2.8 RISANKIZUMAB 132
6.2.8.1 Increased biologic-naïve patient growth and high demand for targeted immunotherapies to fuel adoption 132
6.2.9 OTHER MONOCLONAL ANTIBODIES 135
6.3 GRANULOCYTE COLONY-STIMULATING FACTOR 138
6.3.1 RISING GLOBAL CANCER BURDEN AND INCREASING INVESTMENTS BY PHARMA COMPANIES TO PROPEL MARKET GROWTH 138
6.4 INSULIN 142
6.4.1 HIGH PREVALENCE OF DIABETES TO BOOST MARKET GROWTH 142
6.5 ERYTHROPOIETIN 145
6.5.1 RISING INCIDENCE OF BLOOD DISEASES TO AUGMENT MARKET GROWTH 145
6.6 RECOMBINANT HUMAN GROWTH HORMONE 149
6.6.1 RISING INCIDENCE OF CACHEXIA AND LIVER DISEASES TO FUEL
MARKET GROWTH 149
6.7 ETANERCEPT 152
6.7.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES TO DRIVE APPROVAL AND COMMERCIALIZATION OF ETANERCEPT BIOSIMILARS 152
6.8 FOLLITROPIN 154
6.8.1 POPULARITY OF FOLLITROPIN IN INFERTILITY TREATMENT TO
SPUR MARKET GROWTH 154
6.9 TERIPARATIDE 157
6.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS TO BOOST MARKET DEMAND 157
6.10 INTERFERONS 160
6.10.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO SUPPORT
MARKET GROWTH 160
6.11 ANTICOAGULANTS 163
6.11.1 RISING PREVALENCE OF CARDIOVASCULAR DISEASES TO FUEL
MARKET GROWTH 163
6.12 AFLIBERCEPT 166
6.12.1 HIGH COST OF ORIGINATOR DRUG AND INCREASED PREVALENCE OF AGE-RELATED EYE DISEASES TO DRIVE SEGMENT 166
6.13 GLP-1 ANTAGONIST 169
6.13.1 HIGH PREVALENCE OF DIABETES AND OBESITY TO AID MARKET GROWTH 169
6.14 OTHER DRUG CLASSES 172
7 BIOSIMILARS MARKET, BY INDICATION 176
7.1 INTRODUCTION 177
7.2 ONCOLOGY 177
7.2.1 HIGH PREVALENCE OF CANCER TO DRIVE MARKET 177
7.3 INFLAMMATORY & AUTOIMMUNE DISEASES 181
7.3.1 RISING LIFE EXPECTANCY AND GROWING GERIATRIC POPULATION TO AUGMENT MARKET GROWTH 181
7.4 CHRONIC DISEASES 184
7.4.1 HIGH BURDEN OF CARDIOVASCULAR DISEASES TO FUEL
UPTAKE OF BIOSIMILARS 184
7.5 BLOOD DISORDERS 187
7.5.1 INCREASING INCIDENCE OF BLOOD DISORDERS TO BOOST
BIOSIMILAR DEMAND 187
7.6 GROWTH HORMONE DEFICIENCY 190
7.6.1 INCREASING CASES OF GROWTH HORMONE DEFICIENCY AMONG ADULTS TO INCREASE DEMAND FOR BIOSIMILARS 190
7.7 INFECTIOUS DISEASES 193
7.7.1 HIGH POPULATION DENSITY AND INDUSTRIALIZATION OF FOOD PRODUCTION TO DRIVE PREVALENCE IN EMERGING ECONOMIES 193
7.8 TYPE II DIABETES 196
7.8.1 COST-EFFECTIVENESS AND HIGH EFFICACY TO DRIVE BIOSIMILAR
ADOPTION FOR DIABETES 196
7.9 OBESITY 199
7.9.1 INCREASING SEDENTARY LIFESTYLE AMONG ADULTS TO
PROPEL MARKET GROWTH 199
7.10 OTHER INDICATIONS 202
8 BIOSIMILARS MARKET, BY REGION 206
8.1 INTRODUCTION 207
8.2 EUROPE 207
8.2.1 MACROECONOMIC OUTLOOK FOR EUROPE 208
8.2.2 GERMANY 213
8.2.2.1 Acceptance of biosimilars by physicians over originator products to propel market growth 213
8.2.3 UK 216
8.2.3.1 Rising prevalence of life-threatening diseases to fuel demand for low-priced biosimilars 216
8.2.4 FRANCE 219
8.2.4.1 Increased government R&D investments for biosimilar drugs to augment market growth 219
8.2.5 ITALY 222
8.2.5.1 Favorable government regulations and reimbursement policies to propel market growth 222
8.2.6 SPAIN 225
8.2.6.1 Favorable patient incentives and high healthcare R&D expenditure to promote biosimilar use 225
8.2.7 REST OF EUROPE 228
8.3 ASIA PACIFIC 231
8.3.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 231
8.3.2 JAPAN 235
8.3.2.1 High demand for affordable biologics and recent patent expiries of blockbuster biologics to drive market 235
8.3.3 CHINA 238
8.3.3.1 Increasing investments in pharmaceutical R&D and innovation to augment market growth 238
8.3.4 INDIA 241
8.3.4.1 Need for government healthcare expenditure reduction to propel adoption of biosimilars 241
8.3.5 SOUTH KOREA 244
8.3.5.1 Favourable government incentives to promote biosimilar use in clinical practice 244
8.3.6 AUSTRALIA 247
8.3.6.1 Launch of biosimilar-switching programs in healthcare settings to aid market adoption 247
8.3.7 REST OF ASIA PACIFIC 250
8.4 NORTH AMERICA 253
8.4.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 253
8.4.2 US 258
8.4.2.1 US to dominate North American biosimilars market
during forecast period 258
8.4.3 CANADA 262
8.4.3.1 Favorable government initiatives to drive growth in biopharma research and manufacturing facilities 262
8.5 LATIN AMERICA 265
8.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 265
8.5.2 BRAZIL 269
8.5.2.1 Increased government pharmaceutical R&D investments for biosimilars to aid market growth 269
8.5.3 MEXICO 272
8.5.3.1 Well-developed regulatory landscape and high demand for chronic disease treatment to fuel biosimilar uptake 272
8.5.4 REST OF LATIN AMERICA 275
8.6 MIDDLE EAST 277
8.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 277
8.6.2 GCC COUNTRIES 281
8.6.2.1 Focus on local pharmaceutical R&D to augment market growth 281
8.6.3 REST OF MIDDLE EAST 283
8.7 AFRICA 285
8.7.1 INCREASED CANCER BURDEN AND NEED FOR AFFORDABLE ALTERNATIVES TO HIGH-COST BIOLOGICS TO BOOST ADOPTION 285
8.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 285
9 COMPETITIVE LANDSCAPE 288
9.1 INTRODUCTION 288
9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 288
9.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN
BIOSIMILARS MARKET, 2022−2024 288
9.3 REVENUE ANALYSIS, 2020–2024 290
9.4 MARKET SHARE ANALYSIS, 2024 291
9.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 293
9.5.1 STARS 293
9.5.2 EMERGING LEADERS 293
9.5.3 PERVASIVE PLAYERS 293
9.5.4 PARTICIPANTS 293
9.5.5 COMPETITIVE BENCHMARKING: KEY PLAYERS, 2024 295
9.5.5.1 Company footprint 295
9.5.5.2 Region footprint 296
9.5.5.3 Drug class footprint 297
9.5.5.4 Indication footprint 298
9.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 299
9.6.1 PROGRESSIVE COMPANIES 299
9.6.2 RESPONSIVE COMPANIES 299
9.6.3 DYNAMIC COMPANIES 299
9.6.4 STARTING BLOCKS 299
9.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 301
9.6.5.1 Detailed list of key startups/SMEs 301
9.6.5.2 Competitive benchmarking of key startups/SMEs 302
9.7 COMPANY VALUATION & FINANCIAL METRICS 303
9.7.1 FINANCIAL METRICS 303
9.7.2 COMPANY VALUATION 303
9.8 BRAND/PRODUCT COMPARISON 304
9.9 COMPETITIVE SCENARIO 305
9.9.1 PRODUCT LAUNCHES AND APPROVALS 305
9.9.2 DEALS 306
9.9.3 EXPANSIONS 306
10 COMPANY PROFILES 308
10.1 KEY PLAYERS 308
10.1.1 SANDOZ GROUP AG 308
10.1.1.1 Business overview 308
10.1.1.2 Products offered 309
10.1.1.3 Recent developments 310
10.1.1.3.1 Product launches and approvals 310
10.1.1.3.2 Deals 311
10.1.1.3.3 Expansions 311
10.1.1.3.4 Other developments 312
10.1.1.4 MnM view 312
10.1.1.4.1 Key strengths 312
10.1.1.4.2 Strategic choices 312
10.1.1.4.3 Weaknesses & competitive threats 312
10.1.2 PFIZER INC. 313
10.1.2.1 Business overview 313
10.1.2.2 Products offered 314
10.1.2.3 Recent developments 315
10.1.2.3.1 Product approvals 315
10.1.2.3.2 Deals 316
10.1.2.4 MnM view 316
10.1.2.4.1 Key strengths 316
10.1.2.4.2 Strategic choices 316
10.1.2.4.3 Weaknesses & competitive threats 317
10.1.3 AMGEN INC. 318
10.1.3.1 Business overview 318
10.1.3.2 Products offered 319
10.1.3.3 Products in pipeline 320
10.1.3.4 Recent developments 320
10.1.3.4.1 Product launches and approvals 320
10.1.3.4.2 Deals 321
10.1.3.4.3 Expansions 321
10.1.3.5 MnM view 321
10.1.3.5.1 Key strengths 321
10.1.3.5.2 Strategic choices 322
10.1.3.5.3 Weaknesses & competitive threats 322
10.1.4 CELLTRION INC. 323
10.1.4.1 Business overview 323
10.1.4.2 Products offered 324
10.1.4.3 Recent developments 325
10.1.4.3.1 Product launches and approvals 325
10.1.4.3.2 Deals 326
10.1.4.4 MnM view 326
10.1.4.4.1 Key strengths 326
10.1.4.4.2 Strategic choices 327
10.1.4.4.3 Weaknesses & competitive threats 327
10.1.5 BIOCON 328
10.1.5.1 Business overview 328
10.1.5.2 Products offered 329
10.1.5.3 Recent developments 331
10.1.5.3.1 Product approvals 331
10.1.5.3.2 Deals 331
10.1.5.3.3 Other developments 332
10.1.5.4 MnM view 332
10.1.5.4.1 Key strengths 332
10.1.5.4.2 Strategic choices 332
10.1.5.4.3 Weaknesses & competitive threats 332
10.1.6 DR. REDDY’S LABORATORIES LTD. 333
10.1.6.1 Business overview 333
10.1.6.2 Products offered 334
10.1.6.3 Recent developments 335
10.1.6.3.1 Product launches 335
10.1.6.3.2 Deals 335
10.1.6.3.3 Other developments 336
10.1.7 ELI LILLY AND COMPANY 337
10.1.7.1 Business overview 337
10.1.7.2 Products offered 338
10.1.7.3 Recent developments 339
10.1.7.3.1 Product launches 339
10.1.7.3.2 Deals 339
10.1.7.3.3 Expansions 339
10.1.8 TEVA PHARMACEUTICAL INDUSTRIES LTD. 340
10.1.8.1 Business overview 340
10.1.8.2 Products offered 341
10.1.8.3 Recent developments 341
10.1.8.3.1 Product launches and approvals 341
10.1.8.3.2 Deals 342
10.1.8.3.3 Other developments 342
10.1.9 FRESENIUS KABI AG 343
10.1.9.1 Business overview 343
10.1.9.2 Products offered 344
10.1.9.3 Recent developments 345
10.1.9.3.1 Product launches and approvals 345
10.1.9.3.2 Deals 346
10.1.10 STADA ARZNEIMITTEL AG 347
10.1.10.1 Business overview 347
10.1.10.2 Products offered 348
10.1.10.3 Recent developments 349
10.1.10.3.1 Product launches 349
10.1.10.3.2 Deals 349
10.1.10.3.3 Expansions 350
10.1.10.3.4 Other developments 350
10.1.11 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 351
10.1.11.1 Business overview 351
10.1.11.2 Products offered 352
10.1.11.3 Recent developments 353
10.1.11.3.1 Product approvals 353
10.1.11.3.2 Deals 353
10.1.11.3.3 Expansions 353
10.1.12 SAMSUNG BIOLOGICS 354
10.1.12.1 Business overview 354
10.1.12.2 Products offered 355
10.1.12.3 Recent developments 357
10.1.12.3.1 Product approvals 357
10.1.12.3.2 Deals 358
10.1.12.3.3 Expansions 358
10.1.13 AMNEAL PHARMACEUTICALS LLC 359
10.1.13.1 Business overview 359
10.1.13.2 Products offered 360
10.1.13.3 Recent developments 360
10.1.13.3.1 Product approvals 360
10.1.13.3.2 Deals 360
10.1.13.3.3 Other developments 361
10.1.14 COHERUS BIOSCIENCES 362
10.1.14.1 Business overview 362
10.1.14.2 Products offered 363
10.1.14.3 Recent developments 363
10.1.14.3.1 Deals 363
10.1.14.3.2 Other developments 363
10.1.15 BIO THERA SOLUTIONS 364
10.1.15.1 Business overview 364
10.1.15.2 Products offered 365
10.1.15.3 Recent developments 365
10.1.15.3.1 Product approvals 365
10.1.15.3.2 Deals 366
10.1.16 APROGEN 367
10.1.16.1 Business overview 367
10.1.16.2 Products offered 367
10.1.16.3 Recent developments 367
10.1.16.3.1 Product approvals 367
10.1.16.4 Products in pipeline 368
10.1.17 SHANGHAI HENLINUS BIOTECH, INC. 369
10.1.17.1 Business overview 369
10.1.17.2 Products offered 370
10.1.17.3 Products in pipeline 370
10.1.17.4 Recent developments 370
10.1.17.4.1 Product approvals 370
10.1.17.4.2 Deals 371
10.1.17.4.3 Other developments 371
10.2 OTHER PLAYERS 372
10.2.1 ALVOTECH 372
10.2.2 AMEGA BIOTECH 373
10.2.3 BIOCAD 374
10.2.4 PROBIOMED S.A. DE C.V. 375
10.2.5 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD. 375
10.2.6 POLPHARMA BIOLOGICS GROUP 376
10.2.7 NEUCLONE 377
10.2.8 XENTRIA 378
10.2.9 YL BIOLOGICS 379
10.2.10 KASHIV BIOSCIENCES, LLC 380
10.2.11 NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC 381
10.2.12 SYNERMORE BIOLOGICS (SUZHOU) CO., LTD. 382
10.2.13 CURATEQ BIOLOGICS PVT. LTD. 383
11 APPENDIX 384
11.1 DISCUSSION GUIDE 384
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 388
11.3 CUSTOMIZATION OPTIONS 390
11.4 RELATED REPORTS 390
11.5 AUTHOR DETAILS 391
LIST OF TABLES
TABLE 1 BIOSIMILARS MARKET: INCLUSIONS & EXCLUSIONS 36
TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 48
TABLE 3 BIOSIMILARS MARKET: RISK ANALYSIS 52
TABLE 4 BIOSIMILARS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 61
TABLE 5 LIST OF KEY BIOSIMILARS APPROVED BY MAJOR PLAYERS, 2023–2025 63
TABLE 6 LIST OF IMPENDING AND ONGOING PATENT EXPIRIES OF BLOCKBUSTER BIOLOGICS, 2023–2035 65
TABLE 7 COMPARISON AMONG DIFFERENT DRUG TYPES, INVESTMENTS, APPROVAL TIMES, AND NUMBER OF PATIENTS IN STUDIES 67
TABLE 8 BIOSIMILARS MARKET: ROLE IN ECOSYSTEM 76
TABLE 9 BIOSIMILARS MARKET: NUMBER OF PATENTS FILED
(APPLIED/GRANTED), 2014–2024 77
TABLE 10 BIOSIMILARS MARKET: INDICATIVE LIST OF KEY PATENTS, 2024 78
TABLE 11 BIOSIMILARS MARKET: PRODUCTS IN CLINICAL PIPELINE 80
TABLE 12 BIOSIMILARS MARKET: LIST OF KEY BIOLOGICS TO GO OFF-PATENT, 2025–2035 83
TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 84
TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 84
TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
TABLE 17 BIOSIMILARS MARKET: COUNTRY/REGION-WISE REGULATORY FRAMEWORK 86
TABLE 18 US: REIMBURSEMENT SCENARIO FOR RECENTLY LAUNCHED BIOSIMILARS,
2024–2025 89
TABLE 19 US: REIMBURSEMENT CODES FOR BIOSIMILAR PRODUCTS 90
TABLE 20 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY KEY PLAYER, 2022–2024 (USD) 92
TABLE 21 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, BY REGION,
2022–2024 (USD) 93
TABLE 22 BIOSIMILARS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS,
JANUARY 2025–DECEMBER 2026 95
TABLE 23 BIOSIMILARS MARKET: PORTER’S FIVE FORCES 97
TABLE 24 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY DRUG CLASS (%) 98
TABLE 25 KEY BUYING CRITERIA FOR BIOSIMILAR PRODUCTS, BY END USER 100
TABLE 26 US ADJUSTED RECIPROCAL TARIFF RATES 103
TABLE 27 BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 108
TABLE 28 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2023–2035 (USD MILLION) 109
TABLE 29 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION,
2023–2035 (USD MILLION) 110
TABLE 30 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY, 2023–2035 (USD MILLION) 110
TABLE 31 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2035 (USD MILLION) 111
TABLE 32 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY, 2023–2035 (USD MILLION) 111
TABLE 33 LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY, 2023–2035 (USD MILLION) 112
TABLE 34 MIDDLE EAST: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2035 (USD MILLION) 112
TABLE 35 RITUXIMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 113
TABLE 36 NORTH AMERICA: RITUXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 113
TABLE 37 EUROPE: RITUXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 114
TABLE 38 ASIA PACIFIC: RITUXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 114
TABLE 39 LATIN AMERICA: RITUXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 115
TABLE 40 MIDDLE EAST: RITUXIMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 115
TABLE 41 INFLIXIMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 116
TABLE 42 NORTH AMERICA: INFLIXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 116
TABLE 43 EUROPE: INFLIXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 116
TABLE 44 ASIA PACIFIC: INFLIXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 117
TABLE 45 LATIN AMERICA: INFLIXIMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 117
TABLE 46 MIDDLE EAST: INFLIXIMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 117
TABLE 47 ADALIMUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 118
TABLE 48 NORTH AMERICA: ADALIMUMAB MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 119
TABLE 49 EUROPE: ADALIMUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 119
TABLE 50 ASIA PACIFIC: ADALIMUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 120
TABLE 51 LATIN AMERICA: ADALIMUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 120
TABLE 52 MIDDLE EAST: ADALIMUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 120
TABLE 53 TRASTUZUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 121
TABLE 54 NORTH AMERICA: TRASTUZUMAB MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 122
TABLE 55 EUROPE: TRASTUZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 122
TABLE 56 ASIA PACIFIC: TRASTUZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 123
TABLE 57 LATIN AMERICA: TRASTUZUMAB MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 123
TABLE 58 MIDDLE EAST: TRASTUZUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 123
TABLE 59 PEMBROLIZUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 124
TABLE 60 NORTH AMERICA: PEMBROLIZUMAB MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 124
TABLE 61 EUROPE: PEMBROLIZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 125
TABLE 62 ASIA PACIFIC: PEMBROLIZUMAB MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 125
TABLE 63 LATIN AMERICA: PEMBROLIZUMAB MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 126
TABLE 64 MIDDLE EAST: PEMBROLIZUMAB MARKET, BY REGION,
2023–2035 (USD MILLION) 126
TABLE 65 DUPILUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 127
TABLE 66 NORTH AMERICA: DUPILUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 127
TABLE 67 EUROPE: DUPILUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 128
TABLE 68 ASIA PACIFIC: DUPILUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 128
TABLE 69 LATIN AMERICA: DUPILUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 129
TABLE 70 MIDDLE EAST: DUPILUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 129
TABLE 71 USTEKINUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 130
TABLE 72 NORTH AMERICA: USTEKINUMAB MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 130
TABLE 73 EUROPE: USTEKINUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 131
TABLE 74 ASIA PACIFIC: USTEKINUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 131
TABLE 75 LATIN AMERICA: USTEKINUMAB MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 132
TABLE 76 MIDDLE EAST: USTEKINUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 132
TABLE 77 RISANKIZUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 133
TABLE 78 NORTH AMERICA: RISANKIZUMAB MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 133
TABLE 79 EUROPE: RISANKIZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 133
TABLE 80 ASIA PACIFIC: RISANKIZUMAB MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 134
TABLE 81 LATIN AMERICA: RISANKIZUMAB MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 134
TABLE 82 MIDDLE EAST: RISANKIZUMAB MARKET, BY REGION, 2023–2035 (USD MILLION) 134
TABLE 83 OTHER MONOCLONAL ANTIBODIES MARKET, BY REGION,
2023–2035 (USD MILLION) 136
TABLE 84 NORTH AMERICA: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 136
TABLE 85 EUROPE: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 137
TABLE 86 ASIA PACIFIC: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 137
TABLE 87 LATIN AMERICA: OTHER MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 138
TABLE 88 MIDDLE EAST: OTHER MONOCLONAL ANTIBODIES MARKET, BY REGION,
2023–2035 (USD MILLION) 138
TABLE 89 LIST OF APPROVED BIOSIMILARS FOR GRANULOCYTE COLONY-
STIMULATING FACTOR (G-CSF) 139
TABLE 90 BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR,
BY REGION, 2023–2035 (USD MILLION) 140
TABLE 91 NORTH AMERICA: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2023–2035 (USD MILLION) 140
TABLE 92 EUROPE: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2023–2035 (USD MILLION) 141
TABLE 93 ASIA PACIFIC: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2023–2035 (USD MILLION) 141
TABLE 94 LATIN AMERICA: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2023–2035 (USD MILLION) 142
TABLE 95 MIDDLE EAST: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2023–2035 (USD MILLION) 142
TABLE 96 BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2023–2035 (USD MILLION) 143
TABLE 97 NORTH AMERICA: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY,
2023–2035 (USD MILLION) 143
TABLE 98 EUROPE: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY,
2023–2035 (USD MILLION) 144
TABLE 99 ASIA PACIFIC: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY,
2023–2035 (USD MILLION) 144
TABLE 100 LATIN AMERICA: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY,
2023–2035 (USD MILLION) 145
TABLE 101 MIDDLE EAST: BIOSIMILARS MARKET FOR INSULIN, BY REGION,
2023–2035 (USD MILLION) 145
TABLE 102 LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN 146
TABLE 103 BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION,
2023–2035 (USD MILLION) 146
TABLE 104 NORTH AMERICA: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2023–2035 (USD MILLION) 147
TABLE 105 EUROPE: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY,
2023–2035 (USD MILLION) 147
TABLE 106 ASIA PACIFIC: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY,
2023–2035 (USD MILLION) 148
TABLE 107 LATIN AMERICA: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2023–2035 (USD MILLION) 148
TABLE 108 MIDDLE EAST: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION,
2023–2035 (USD MILLION) 148
TABLE 109 BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE,
BY REGION, 2023–2035 (USD MILLION) 149
TABLE 110 NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2023–2035 (USD MILLION) 150
TABLE 111 EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2023–2035 (USD MILLION) 150
TABLE 112 ASIA PACIFIC: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2023–2035 (USD MILLION) 151
TABLE 113 LATIN AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2023–2035 (USD MILLION) 151
TABLE 114 MIDDLE EAST: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2023–2035 (USD MILLION) 151
TABLE 115 BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 2023–2035 (USD MILLION) 152
TABLE 116 NORTH AMERICA: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY,
2023–2035 (USD MILLION) 152
TABLE 117 EUROPE: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY,
2023–2035 (USD MILLION) 153
TABLE 118 ASIA PACIFIC: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY,
2023–2035 (USD MILLION) 153
TABLE 119 LATIN AMERICA: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY,
2023–2035 (USD MILLION) 154
TABLE 120 MIDDLE EAST: BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION,
2023–2035 (USD MILLION) 154
TABLE 121 BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2023–2035 (USD MILLION) 155
TABLE 122 NORTH AMERICA: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY,
2023–2035 (USD MILLION) 155
TABLE 123 EUROPE: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY,
2023–2035 (USD MILLION) 156
TABLE 124 ASIA PACIFIC: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY,
2023–2035 (USD MILLION) 156
TABLE 125 LATIN AMERICA: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY,
2023–2035 (USD MILLION) 157
TABLE 126 MIDDLE EAST: BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION,
2023–2035 (USD MILLION) 157
TABLE 127 BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION,
2023–2035 (USD MILLION) 158
TABLE 128 NORTH AMERICA: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY,
2023–2035 (USD MILLION) 158
TABLE 129 EUROPE: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY,
2023–2035 (USD MILLION) 159
TABLE 130 ASIA PACIFIC: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY,
2023–2035 (USD MILLION) 159
TABLE 131 LATIN AMERICA: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY,
2023–2035 (USD MILLION) 160
TABLE 132 MIDDLE EAST: BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION,
2023–2035 (USD MILLION) 160
TABLE 133 BIOSIMILARS MARKET FOR INTERFERONS, BY REGION,
2023–2035 (USD MILLION) 161
TABLE 134 NORTH AMERICA: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY,
2023–2035 (USD MILLION) 161
TABLE 135 EUROPE: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY,
2023–2035 (USD MILLION) 162
TABLE 136 ASIA PACIFIC: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY,
2023–2035 (USD MILLION) 162
TABLE 137 LATIN AMERICA: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY,
2023–2035 (USD MILLION) 163
TABLE 138 MIDDLE EAST: BIOSIMILARS MARKET FOR INTERFERONS, BY REGION,
2023–2035 (USD MILLION) 163
TABLE 139 BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY REGION,
2023–2035 (USD MILLION) 164
TABLE 140 NORTH AMERICA: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2023–2035 (USD MILLION) 164
TABLE 141 EUROPE: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY,
2023–2035 (USD MILLION) 165
TABLE 142 ASIA PACIFIC: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY,
2023–2035 (USD MILLION) 165
TABLE 143 LATIN AMERICA: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2023–2035 (USD MILLION) 166
TABLE 144 MIDDLE EAST: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY REGION,
2023–2035 (USD MILLION) 166
TABLE 145 BIOSIMILARS MARKET FOR AFLIBERCEPT, BY REGION, 2023–2035 (USD MILLION) 167
TABLE 146 NORTH AMERICA: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY,
2023–2035 (USD MILLION) 167
TABLE 147 EUROPE: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY,
2023–2035 (USD MILLION) 168
TABLE 148 ASIA PACIFIC: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY,
2023–2035 (USD MILLION) 168
TABLE 149 LATIN AMERICA: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY COUNTRY,
2023–2035 (USD MILLION) 169
TABLE 150 MIDDLE EAST: BIOSIMILARS MARKET FOR AFLIBERCEPT, BY REGION,
2023–2035 (USD MILLION) 169
TABLE 151 BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY REGION,
2023–2035 (USD MILLION) 170
TABLE 152 NORTH AMERICA: BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY COUNTRY, 2023–2035 (USD MILLION) 170
TABLE 153 EUROPE: BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY COUNTRY,
2023–2035 (USD MILLION) 171
TABLE 154 ASIA PACIFIC: BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY COUNTRY, 2023–2035 (USD MILLION) 171
TABLE 155 LATIN AMERICA: BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY COUNTRY, 2023–2035 (USD MILLION) 172
TABLE 156 MIDDLE EAST: BIOSIMILARS MARKET FOR GLP-1 ANTAGONIST, BY REGION,
2023–2035 (USD MILLION) 172
TABLE 157 BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY REGION,
2023–2035 (USD MILLION) 173
TABLE 158 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES,
BY COUNTRY, 2023–2035 (USD MILLION) 173
TABLE 159 EUROPE: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY,
2023–2035 (USD MILLION) 174
TABLE 160 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2023–2035 (USD MILLION) 174
TABLE 161 LATIN AMERICA: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2023–2035 (USD MILLION) 175
TABLE 162 MIDDLE EAST: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY REGION, 2023–2035 (USD MILLION) 175
TABLE 163 BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 177
TABLE 164 BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2023–2035 (USD MILLION) 178
TABLE 165 NORTH AMERICA: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY,
2023–2035 (USD MILLION) 179
TABLE 166 EUROPE: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY,
2023–2035 (USD MILLION) 179
TABLE 167 ASIA PACIFIC: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY,
2023–2035 (USD MILLION) 180
TABLE 168 LATIN AMERICA: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY,
2023–2035 (USD MILLION) 180
TABLE 169 MIDDLE EAST: BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION,
2023–2035 (USD MILLION) 181
TABLE 170 BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES,
BY REGION, 2023–2035 (USD MILLION) 182
TABLE 171 NORTH AMERICA: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 182
TABLE 172 EUROPE: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 183
TABLE 173 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 183
TABLE 174 LATIN AMERICA: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 184
TABLE 175 MIDDLE EAST: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2023–2035 (USD MILLION) 184
TABLE 176 BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION,
2023–2035 (USD MILLION) 185
TABLE 177 NORTH AMERICA: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 185
TABLE 178 EUROPE: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY,
2023–2035 (USD MILLION) 186
TABLE 179 ASIA PACIFIC: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 186
TABLE 180 LATIN AMERICA: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 187
TABLE 181 MIDDLE EAST: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION,
2023–2035 (USD MILLION) 187
TABLE 182 BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION,
2023–2035 (USD MILLION) 188
TABLE 183 NORTH AMERICA: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2023–2035 (USD MILLION) 188
TABLE 184 EUROPE: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY,
2023–2035 (USD MILLION) 189
TABLE 185 ASIA PACIFIC: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2023–2035 (USD MILLION) 189
TABLE 186 LATIN AMERICA: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2023–2035 (USD MILLION) 190
TABLE 187 MIDDLE EAST: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION,
2023–2035 (USD MILLION) 190
TABLE 188 BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION,
2023–2035 (USD MILLION) 191
TABLE 189 NORTH AMERICA: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,
BY COUNTRY, 2023–2035 (USD MILLION) 191
TABLE 190 EUROPE: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,
BY COUNTRY, 2023–2035 (USD MILLION) 192
TABLE 191 ASIA PACIFIC: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,
BY COUNTRY, 2023–2035 (USD MILLION) 192
TABLE 192 LATIN AMERICA: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,
BY COUNTRY, 2023–2035 (USD MILLION) 193
TABLE 193 MIDDLE EAST: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,
BY REGION, 2023–2035 (USD MILLION) 193
TABLE 194 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION,
2023–2035 (USD MILLION) 194
TABLE 195 NORTH AMERICA: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2023–2035 (USD MILLION) 194
TABLE 196 EUROPE: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2023–2035 (USD MILLION) 195
TABLE 197 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 195
TABLE 198 LATIN AMERICA: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2035 (USD MILLION) 196
TABLE 199 MIDDLE EAST: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2035 (USD MILLION) 196
TABLE 200 BIOSIMILARS MARKET FOR TYPE II DIABETES, BY REGION,
2023–2035 (USD MILLION) 197
TABLE 201 NORTH AMERICA: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY, 2023–2035 (USD MILLION) 197
TABLE 202 EUROPE: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY,
2023–2035 (USD MILLION) 198
TABLE 203 ASIA PACIFIC: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY,
2023–2035 (USD MILLION) 198
TABLE 204 LATIN AMERICA: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY COUNTRY, 2023–2035 (USD MILLION) 199
TABLE 205 MIDDLE EAST: BIOSIMILARS MARKET FOR TYPE II DIABETES, BY REGION,
2023–2035 (USD MILLION) 199
TABLE 206 BIOSIMILARS MARKET FOR OBESITY, BY REGION, 2023–2035 (USD MILLION) 200
TABLE 207 NORTH AMERICA: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY,
2023–2035 (USD MILLION) 200
TABLE 208 EUROPE: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY,
2023–2035 (USD MILLION) 201
TABLE 209 ASIA PACIFIC: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY,
2023–2035 (USD MILLION) 201
TABLE 210 LATIN AMERICA: BIOSIMILARS MARKET FOR OBESITY, BY COUNTRY,
2023–2035 (USD MILLION) 202
TABLE 211 MIDDLE EAST: BIOSIMILARS MARKET FOR OBESITY, BY REGION,
2023–2035 (USD MILLION) 202
TABLE 212 BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION,
2023–2035 (USD MILLION) 203
TABLE 213 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 203
TABLE 214 EUROPE: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY,
2023–2035 (USD MILLION) 204
TABLE 215 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 204
TABLE 216 LATIN AMERICA: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2035 (USD MILLION) 205
TABLE 217 MIDDLE EAST: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2035 (USD MILLION) 205
TABLE 218 BIOSIMILARS MARKET, BY REGION, 2023–2035 (USD MILLION) 207
TABLE 219 EUROPE: KEY MACROINDICATORS 208
TABLE 220 EUROPE: LIST OF APPROVED BIOSIMILARS, 2022–2025 210
TABLE 221 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 211
TABLE 222 EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 211
TABLE 223 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2023–2035 (USD MILLION) 212
TABLE 224 EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 212
TABLE 225 GERMANY: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 214
TABLE 226 GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 215
TABLE 227 GERMANY: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 215
TABLE 228 UK: LIST OF APPROVED BIOSIMILARS, 2022–2025 216
TABLE 229 UK: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 217
TABLE 230 UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2023–2035 (USD MILLION) 218
TABLE 231 UK: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 218
TABLE 232 FRANCE: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 220
TABLE 233 FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2023–2035 (USD MILLION) 221
TABLE 234 FRANCE: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 221
TABLE 235 ITALY: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 223
TABLE 236 ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2023–2035 (USD MILLION) 224
TABLE 237 ITALY: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 224
TABLE 238 SPAIN: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 226
TABLE 239 SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2023–2035 (USD MILLION) 227
TABLE 240 SPAIN: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 227
TABLE 241 REST OF EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS,
2023–2035 (USD MILLION) 229
TABLE 242 REST OF EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2023–2035 (USD MILLION) 230
TABLE 243 REST OF EUROPE: BIOSIMILARS MARKET, BY INDICATION,
2023–2035 (USD MILLION) 230
TABLE 244 ASIA PACIFIC: KEY MACROINDICATORS 232
TABLE 245 ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 232
TABLE 246 ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 233
TABLE 247 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 234
TABLE 248 ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 234
TABLE 249 JAPAN: LIST OF APPROVED BIOSIMILARS, 2022–2025 236
TABLE 250 JAPAN: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 236
TABLE 251 JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2023–2035 (USD MILLION) 237
TABLE 252 JAPAN: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 237
TABLE 253 CHINA: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 239
TABLE 254 CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2023–2035 (USD MILLION) 240
TABLE 255 CHINA: BIOSIMILARS MARKET, BY INDICATION, 2023–2025 (USD MILLION) 240
TABLE 256 INDIA: BIOSIMILARS APPROVED AND MARKETED, 2022–2025 241
TABLE 257 INDIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 242
TABLE 258 INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2023–2035 (USD MILLION) 243
TABLE 259 INDIA: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 243
TABLE 260 SOUTH KOREA: LIST OF APPROVED BIOSIMILARS, 2022–2025 244
TABLE 261 SOUTH KOREA: BIOSIMILARS MARKET, BY DRUG CLASS,
2023–2035 (USD MILLION) 245
TABLE 262 SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 246
TABLE 263 SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION,
2023–2035 (USD MILLION) 246
TABLE 264 AUSTRALIA: LIST OF APPROVED BIOSIMILARS, 2022–2025 247
TABLE 265 AUSTRALIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 248
TABLE 266 AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 249
TABLE 267 AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 249
TABLE 268 NEW ZEALAND: LIST OF APPROVED BIOSIMILARS, 2022–2025 250
TABLE 269 MALAYSIA: LIST OF APPROVED BIOSIMILARS, 2022–2025 250
TABLE 270 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS,
2023–2035 (USD MILLION) 251
TABLE 271 REST OF ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2023–2035 (USD MILLION) 252
TABLE 272 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION,
2023–2035 (USD MILLION) 252
TABLE 273 NORTH AMERICA: KEY MACROINDICATORS 254
TABLE 274 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY,
2023–2035 (USD MILLION) 255
TABLE 275 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS,
2023–2035 (USD MILLION) 256
TABLE 276 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2023–2035 (USD MILLION) 257
TABLE 277 NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION,
2023–2035 (USD MILLION) 257
TABLE 278 US: LIST OF APPROVED BIOSIMILARS, 2022–2025 258
TABLE 279 US: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 260
TABLE 280 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2023–2035 (USD MILLION) 261
TABLE 281 US: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 261
TABLE 282 CANADA: LIST OF APPROVED BIOSIMILARS, 2022–2025 262
TABLE 283 CANADA: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 263
TABLE 284 CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2023–2035 (USD MILLION) 264
TABLE 285 CANADA: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 264
TABLE 286 LATIN AMERICA: KEY MACROINDICATORS 266
TABLE 287 LATIN AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2023–2035 (USD MILLION) 266
TABLE 288 LATIN AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS,
2023–2035 (USD MILLION) 267
TABLE 289 LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 268
TABLE 290 LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION,
2023–2035 (USD MILLION) 268
TABLE 291 BRAZIL: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 270
TABLE 292 BRAZIL: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2023–2035 (USD MILLION) 271
TABLE 293 BRAZIL: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 271
TABLE 294 MEXICO: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 273
TABLE 295 MEXICO: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2023–2035 (USD MILLION) 274
TABLE 296 MEXICO: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 274
TABLE 297 REST OF LATIN AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS,
2023–2035 (USD MILLION) 275
TABLE 298 REST OF LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 276
TABLE 299 REST OF LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION,
2023–2035 (USD MILLION) 276
TABLE 300 MIDDLE EAST: KEY MACROINDICATORS 278
TABLE 301 MIDDLE EAST: BIOSIMILARS MARKET, BY REGION, 2023–2035 (USD MILLION) 278
TABLE 302 MIDDLE EAST: BIOSIMILARS MARKET, BY DRUG CLASS,
2023–2035 (USD MILLION) 279
TABLE 303 MIDDLE EAST: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 280
TABLE 304 MIDDLE EAST: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 280
TABLE 305 GCC COUNTRIES: BIOSIMILARS MARKET, BY DRUG CLASS,
2023–2035 (USD MILLION) 281
TABLE 306 GCC COUNTRIES: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2023–2035 (USD MILLION) 282
TABLE 307 GCC COUNTRIES: BIOSIMILARS MARKET, BY INDICATION,
2023–2035 (USD MILLION) 282
TABLE 308 REST OF MIDDLE EAST: BIOSIMILARS MARKET, BY DRUG CLASS,
2023–2035 (USD MILLION) 283
TABLE 309 REST OF MIDDLE EAST: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2023–2035 (USD MILLION) 284
TABLE 310 REST OF MIDDLE EAST: BIOSIMILARS MARKET, BY INDICATION,
2023–2035 (USD MILLION) 284
TABLE 311 AFRICA: KEY MACROINDICATORS 286
TABLE 312 AFRICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2023–2035 (USD MILLION) 286
TABLE 313 AFRICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2023–2035 (USD MILLION) 287
TABLE 314 AFRICA: BIOSIMILARS MARKET, BY INDICATION, 2023–2035 (USD MILLION) 287
TABLE 315 OVERVIEW OF MAJOR STRATEGIES DEPLOYED BY KEY PLAYERS IN
BIOSIMILARS MARKET, 2022–2024 288
TABLE 316 BIOSIMILARS MARKET: DEGREE OF COMPETITION 292
TABLE 317 BIOSIMILARS MARKET: REGION FOOTPRINT 296
TABLE 318 BIOSIMILARS MARKET: DRUG CLASS FOOTPRINT 297
TABLE 319 BIOSIMILARS MARKET: INDICATION FOOTPRINT 298
TABLE 320 BIOSIMILARS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 301
TABLE 321 BIOSIMILARS MARKET: COMPETITIVE BENCHMARKING OF
KEY STARTUPS/SME PLAYERS, 2024 302
TABLE 322 BIOSIMILARS MARKET: PRODUCT APPROVALS AND LAUNCHES,
JANUARY 2022–APRIL 2025 305
TABLE 323 BIOSIMILARS MARKET: DEALS, JANUARY 2022–APRIL 2025 306
TABLE 324 BIOSIMILARS MARKET: EXPANSIONS, JANUARY 2022– APRIL 2025 306
TABLE 325 SANDOZ GROUP AG: COMPANY OVERVIEW 308
TABLE 326 SANDOZ GROUP AG: PRODUCTS OFFERED 309
TABLE 327 SANDOZ GROUP AG: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–APRIL 2025 310
TABLE 328 SANDOZ GROUP AG: DEALS, JANUARY 2022–APRIL 2025 311
TABLE 329 SANDOZ GROUP AG: EXPANSIONS, JANUARY 2022–APRIL 2025 311
TABLE 330 SANDOZ GROUP AG: OTHER DEVELOPMENTS, JANUARY 2022–APRIL 2025 312
TABLE 331 PFIZER INC.: COMPANY OVERVIEW 313
TABLE 332 PFIZER INC.: PRODUCTS OFFERED 314
TABLE 333 PFIZER INC.: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 315
TABLE 334 PFIZER INC.: DEALS, JANUARY 2022–APRIL 2025 316
TABLE 335 AMGEN INC.: COMPANY OVERVIEW 318
TABLE 336 AMGEN INC.: PRODUCTS OFFERED 319
TABLE 337 AMGEN INC.: PRODUCTS IN PIPELINE 320
TABLE 338 AMGEN INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–APRIL 2025 320
TABLE 339 AMGEN INC.: DEALS, JANUARY 2022–APRIL 2025 321
TABLE 340 AMGEN INC.: EXPANSIONS, JANUARY 2022–APRIL 2025 321
TABLE 341 CELLTRION INC.: COMPANY OVERVIEW 323
TABLE 342 CELLTRION INC.: PRODUCTS OFFERED 324
TABLE 343 CELLTRION INC.: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–APRIL 2025 325
TABLE 344 CELLTRION INC.: DEALS, JANUARY 2022–APRIL 2025 326
TABLE 345 BIOCON: COMPANY OVERVIEW 328
TABLE 346 BIOCON: PRODUCTS OFFERED 329
TABLE 347 BIOCON: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 331
TABLE 348 BIOCON: DEALS, JANUARY 2022–APRIL 2025 331
TABLE 349 BIOCON: OTHER DEVELOPMENTS, JANUARY 2022–APRIL 2025 332
TABLE 350 DR. REDDY’S LABORATORIES LTD.: COMPANY OVERVIEW 333
TABLE 351 DR. REDDY’S LABORATORIES LTD.: PRODUCTS OFFERED 334
TABLE 352 DR. REDDY’S LABORATORIES LTD.: PRODUCT LAUNCHES,
JANUARY 2022–APRIL 2025 335
TABLE 353 DR. REDDY’S LABORATORIES LTD.: DEALS, JANUARY 2022–APRIL 2025 335
TABLE 354 DR. REDDY’S LABORATORIES LTD.: OTHER DEVELOPMENTS,
JANUARY 2022–APRIL 2025 336
TABLE 355 ELI LILLY AND COMPANY: COMPANY OVERVIEW 337
TABLE 356 ELI LILLY AND COMPANY: PRODUCTS OFFERED 338
TABLE 357 ELI LILLY AND COMPANY: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2025 339
TABLE 358 ELI LILLY AND COMPANY: DEALS, JANUARY 2022–APRIL 2025 339
TABLE 359 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–APRIL 2025 339
TABLE 360 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 340
TABLE 361 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 341
TABLE 362 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT LAUNCHES AND
APPROVALS, JANUARY 2022–APRIL 2025 341
TABLE 363 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022–APRIL 2025 342
TABLE 364 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OTHER DEVELOPMENTS,
JANUARY 2022–APRIL 2025 342
TABLE 365 FRESENIUS KABI AG: COMPANY OVERVIEW 343
TABLE 366 FRESENIUS KABI AG: PRODUCTS OFFERED 344
TABLE 367 FRESENIUS KABI AG: PRODUCT LAUNCHES AND APPROVALS,
JANUARY 2022–APRIL 2025 345
TABLE 368 FRESENIUS KABI AG: DEALS, JANUARY 2022–APRIL 2025 346
TABLE 369 STADA ARZEIMITTEL AG: COMPANY OVERVIEW 347
TABLE 370 STADA ARZEIMITTEL AG: PRODUCTS OFFERED 348
TABLE 371 STADA ARZEIMITTEL AG: PRODUCT LAUNCHES, JANUARY 2022–APRIL 2025 349
TABLE 372 STADA ARZEIMITTEL AG: DEALS, JANUARY 2022–APRIL 2025 349
TABLE 373 STADA ARZEIMITTEL AG: EXPANSIONS, JANUARY 2022–APRIL 2025 350
TABLE 374 STADA ARZEIMITTEL AG: OTHER DEVELOPMENTS, JANUARY 2022–APRIL 2025 350
TABLE 375 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW 351
TABLE 376 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED 352
TABLE 377 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 353
TABLE 378 BOEHRINGER INGELHEIM INTERNATIONAL GMBH:
DEALS, JANUARY 2022–APRIL 2025 353
TABLE 379 BOEHRINGER INGELHEIM INTERNATIONAL GMBH:
EXPANSIONS, JANUARY 2022–APRIL 2025 353
TABLE 380 SAMSUNG BIOLOGICS: COMPANY OVERVIEW 354
TABLE 381 SAMSUNG BIOLOGICS: PRODUCTS OFFERED 355
TABLE 382 SAMSUNG BIOLOGICS: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 357
TABLE 383 SAMSUNG BIOLOGICS: DEALS, JANUARY 2022–APRIL 2025 358
TABLE 384 SAMSUNG BIOLOGICS: EXPANSIONS, JANUARY 2022–APRIL 2025 358
TABLE 385 AMNEAL PHARMACEUTICALS LLC: COMPANY OVERVIEW 359
TABLE 386 AMNEAL PHARMACEUTICALS LLC: PRODUCTS OFFERED 360
TABLE 387 AMNEAL PHARMACEUTICALS LLC: PRODUCT APPROVALS,
JANUARY 2022–APRIL 2025 360
TABLE 388 AMNEAL PHARMACEUTICALS LLC: DEALS, JANUARY 2022–APRIL 2025 360
TABLE 389 AMNEAL PHARMACEUTICALS LLC: OTHER DEVELOPMENTS,
JANUARY 2022–APRIL 2025 361
TABLE 390 COHERUS BIOSCIENCES: COMPANY OVERVIEW 362
TABLE 391 COHERUS BIOSCIENCES: PRODUCTS OFFERED 363
TABLE 392 COHERUS BIOSCIENCES: DEALS, JANUARY 2022–APRIL 2025 363
TABLE 393 COHERUS BIOSCIENCES: OTHER DEVELOPMENTS, JANUARY 2022–APRIL 2025 363
TABLE 394 BIO THERA SOLUTIONS: COMPANY OVERVIEW 364
TABLE 395 BIO THERA SOLUTIONS: PRODUCTS OFFERED 365
TABLE 396 BIO THERA SOLUTIONS: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 365
TABLE 397 BIO THERA SOLUTIONS: DEALS, JANUARY 2022–APRIL 2025 366
TABLE 398 APROGEN: COMPANY OVERVIEW 367
TABLE 399 APROGEN: PRODUCTS OFFERED 367
TABLE 400 APROGEN: PRODUCT APPROVALS, JANUARY 2022–APRIL 2025 367
TABLE 401 APROGEN: PRODUCTS IN PIPELINE 368
TABLE 402 SHANGHAI HENLINUS BIOTECH, INC.: COMPANY OVERVIEW 369
TABLE 403 SHANGHAI HENLINUS BIOTECH, INC.: PRODUCTS OFFERED 370
TABLE 404 SHANGHAI HENLINUS BIOTECH, INC.: PRODUCTS IN PIPELINE 370
TABLE 405 SHANGHAI HENLINUS BIOTECH, INC.: PRODUCT APPROVALS,
JANUARY 2022–APRIL 2025 370
TABLE 406 SHANGHAI HENLINUS BIOTECH, INC.: DEALS, JANUARY 2022–APRIL 2025 371
TABLE 407 SHANGHAI HENLINUS BIOTECH, INC.: OTHER DEVELOPMENTS,
JANUARY 2022–APRIL 2025 371
TABLE 408 ALVOTECH: COMPANY OVERVIEW 372
TABLE 409 AMGEGA BIOTECH: COMPANY OVERVIEW 373
TABLE 410 BIOCAD: COMPANY OVERVIEW 374
TABLE 411 PROBIOMED S.A. DE C.V.: COMPANY OVERVIEW 375
TABLE 412 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.: COMPANY OVERVIEW 375
TABLE 413 POLPHARMA BIOLOGICS GROUP: COMPANY OVERVIEW 376
TABLE 414 NEUCLONE: COMPANY OVERVIEW 377
TABLE 415 XENTRIA: COMPANY OVERVIEW 378
TABLE 416 YL BIOLOGICS: COMPANY OVERVIEW 379
TABLE 417 KASHIV BIOSCIENCES, LLC: COMPANY OVERVIEW 380
TABLE 418 NANOGEN PHARMACEUTICAL BIOTECHNOLOGY JSC: COMPANY OVERVIEW 381
TABLE 419 SYNERMORE BIOLOGICS (SUZHOU) CO., LTD.: COMPANY OVERVIEW 382
TABLE 420 CURATEQ BIOLOGICS PVT. LTD.: COMPANY OVERVIEW 383
LIST OF FIGURES
FIGURE 1 BIOSIMILARS MARKET SEGMENTATION & REGIONAL SCOPE 35
FIGURE 2 BIOSIMILARS MARKET: YEARS CONSIDERED 36
FIGURE 3 BIOSIMILARS MARKET: RESEARCH DESIGN 39
FIGURE 4 BIOSIMILARS MARKET: KEY DATA FROM SECONDARY SOURCES 41
FIGURE 5 BIOSIMILARS MARKET: BREAKDOWN OF PRIMARIES (SUPPLY- AND
DEMAND-SIDE PARTICIPANTS) 42
FIGURE 6 BIOSIMILARS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024 43
FIGURE 7 COMPANY REVENUE ANALYSIS-BASED ESTIMATION:
BOTTOM-UP APPROACH (2024) 44
FIGURE 8 REVENUE SHARE ANALYSIS OF SANDOZ GROUP AG (2024) 44
FIGURE 9 BIOSIMILARS MARKET SIZE VALIDATION FROM PRIMARY EXPERTS 46
FIGURE 10 BIOSIMILARS MARKET: TOP-DOWN APPROACH 47
FIGURE 11 BIOSIMILARS MARKET: CAGR PROJECTIONS 48
FIGURE 12 BIOSIMILARS MARKET: DATA TRIANGULATION 50
FIGURE 13 BIOSIMILARS MARKET, BY DRUG CLASS, 2025 VS. 2035 (USD MILLION) 53
FIGURE 14 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2025 VS. 2035 (USD MILLION) 54
FIGURE 15 BIOSIMILARS MARKET, BY INDICATION, 2025 VS. 2035 (USD MILLION) 55
FIGURE 16 REGIONAL SNAPSHOT OF BIOSIMILARS MARKET 56
FIGURE 17 INCREASING INVESTMENTS IN BIOSIMILAR RESEARCH AND GROWING DEMAND FOR COST-EFFECTIVE TREATMENT OPTIONS TO DRIVE MARKET 57
FIGURE 18 US AND MONOCLONAL ANTIBODIES ARE EXPECTED TO ACCOUNT FOR
LARGEST MARKET SHARE IN 2025 58
FIGURE 19 REST OF EUROPE TO REGISTER HIGHEST CAGR FROM 2025 TO 2035 59
FIGURE 20 EMERGING MARKETS TO REGISTER HIGHER GROWTH RATES
DURING STUDY PERIOD 59
FIGURE 21 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 60
FIGURE 22 BIOSIMILARS MARKET: TRENDS/DISRUPTIONS IMPACTING
CUSTOMERS’ BUSINESSES 73
FIGURE 23 BIOSIMILARS MARKET: VALUE CHAIN ANALYSIS 74
FIGURE 24 BIOSIMILARS MARKET: ECOSYSTEM ANALYSIS 76
FIGURE 25 BIOSIMILARS MARKET: PATENT PUBLICATION TRENDS, JURISDICTION,
AND TOP APPLICANT ANALYSIS (JANUARY 2014–DECEMBER 2024) 78
FIGURE 26 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS, 2022–2024 (USD) 93
FIGURE 27 AVERAGE SELLING PRICE TREND OF BIOSIMILAR PRODUCTS,
BY REGION, 2022–2024 (USD) 94
FIGURE 28 BIOSIMILARS MARKET: PORTER’S FIVE FORCES ANALYSIS 96
FIGURE 29 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY DRUG CLASS 98
FIGURE 30 KEY BUYING CRITERIA FOR BIOSIMILAR PRODUCTS, BY END USER 99
FIGURE 31 BIOSIMILARS MARKET: INVESTMENT & FUNDING SCENARIO, 2023–2025 101
FIGURE 32 BIOSIMILARS MARKET: IMPACT OF AI/GEN AI 102
FIGURE 33 EUROPE: BIOSIMILARS MARKET SNAPSHOT 209
FIGURE 34 NORTH AMERICA: BIOSIMILARS MARKET SNAPSHOT 255
FIGURE 35 REVENUE ANALYSIS OF KEY PLAYERS IN BIOSIMILARS MARKET,
2020–2024 (USD MILLION) 290
FIGURE 36 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BIOSIMILARS MARKET (2024) 291
FIGURE 37 BIOSIMILARS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 294
FIGURE 38 BIOSIMILARS MARKET: COMPANY FOOTPRINT 295
FIGURE 39 BIOSIMILARS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 300
FIGURE 40 EV/EBITDA OF KEY VENDORS 303
FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 303
FIGURE 42 BIOSIMILARS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 304
FIGURE 43 SANDOZ GROUP AG: COMPANY SNAPSHOT 309
FIGURE 44 PFIZER INC.: COMPANY SNAPSHOT 314
FIGURE 45 AMGEN INC.: COMPANY SNAPSHOT 319
FIGURE 46 CELLTRION INC.: COMPANY SNAPSHOT 324
FIGURE 47 BIOCON: COMPANY SNAPSHOT 329
FIGURE 48 DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT 334
FIGURE 49 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 338
FIGURE 50 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT 340
FIGURE 51 FRESENIUS KABI AG: COMPANY SNAPSHOT 344
FIGURE 52 STADA ARZEIMITTEL AG: COMPANY SNAPSHOT 348
FIGURE 53 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT 352
FIGURE 54 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT 355
FIGURE 55 AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT 359
FIGURE 56 COHERUS BIOSCIENCES: COMPANY SNAPSHOT 362
FIGURE 57 BIO THERA SOLUTIONS: COMPANY SNAPSHOT 364
FIGURE 58 SHANGHAI HENLINUS BIOTECH, INC.: COMPANY SNAPSHOT 369
MarketsandMarkets(マーケッツアンドマーケッツ)は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間~12時間以内(営業日基準)にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
シングルユーザ | コーポレート |
USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨(定価)を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料(ハンドリングチャージ)無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内(関連会社除く)5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100%持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内(営業日基準)
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- サプライチェーンマネジメント(SCM)市場 – 2030年までの世界予測 2025-07-08
- バイオセンサー市場 – 2030年までの世界予測 2025-07-08
- In situ ハイブリダイゼーション(ISH)市場 – 2030年までの世界予測 2025-07-08
- 燃料電池市場 – 2030年までの世界予測 2025-07-08
- 施設管理市場 – 2030年までの世界予測 2025-07-07